A groundbreaking molecular discovery reveals how cancer cells may hijack normal genetic machinery to fuel tumor growth, potentially explaining why some patients respond better to certain cancer drugs than others. The finding challenges the fundamental assumption that genes produce only one primary protein product per transcript.
Researchers identified a novel cellular process called "RNA dicing" where the JAK1 gene's messenger RNA is cleaved to produce a truncated protein containing only the kinase domain (JH1). This abbreviated version lacks the regulatory domains that normally keep JAK1 activity in check, effectively creating an oncogenic protein fragment from the same gene that produces the full-length, tumor-suppressive JAK1 protein. The balance between these two forms shifts dramatically in cancer, with tumors showing increased production of the dangerous truncated version.
This mechanism represents a paradigm shift in our understanding of how genetic information translates into functional proteins. Traditional molecular biology teaches that each gene produces one primary protein, but RNA dicing demonstrates that cells can generate functionally opposite proteins from identical genetic starting material. The discovery has immediate clinical relevance: endometrial cancer patients whose tumors favor the diced JAK1 variant showed superior responses to momelotinib, a JAK1 inhibitor currently in clinical trials. This suggests RNA dicing patterns could serve as biomarkers for treatment selection, moving precision oncology beyond simple genetic mutations toward understanding how those mutations alter protein production. The finding likely extends beyond JAK1, potentially explaining treatment resistance patterns across multiple cancer types where seemingly identical mutations produce vastly different clinical outcomes.